Oragenics (OGEN) Times Interest Earned (2010 - 2026)
Oragenics' (OGEN) quarterly Times Interest Earned came in at -$605.29 in Q1 2026, down 5848.5% YoY from $10.53 in Q1 2025, and down 80.6% on a QoQ basis from -$335.16 in Q4 2025.
Oragenics (OGEN) Times Interest Earned (2010 - 2026) Analysis & Trends
Oragenics (OGEN) has 17 years of Times Interest Earned data on file, last reported at -$605.29 in Q1 2026.
- Quarterly Times Interest Earned fell 5848.5% year-over-year to -$605.29 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.24 (up 64.41% YoY) and the FY2025 annual result came in at -$0.2, up 92.93% from the prior year.
- Times Interest Earned retreated to -$605.29 in Q1 2026, from -$335.16 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$3.0 in Q2 2025 to a low of -$1279.0 in Q2 2024.
- A 5-year average of -$321.21 and a median of -$305.9 in 2024 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2024 — Times Interest Earned slumped 10853.72% — and 2025, when it surged 99.77%.
- Tracing OGEN's Times Interest Earned over 5 years: stood at -$395.52 in 2022, then decreased by 18.75% to -$469.69 in 2023, then jumped by 34.87% to -$305.9 in 2024, then retreated by 9.57% to -$335.16 in 2025, then plunged by 80.6% to -$605.29 in 2026.
- The last three Times Interest Earned figures came in at -$605.29 (Q1 2026), -$335.16 (Q4 2025), and -$443.78 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Oragenics | 2.31 Mn | 2.31 Mn | - | -6,262.14 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6,262.14 |
| Mar 31, 2026 | -605.29 |
| Dec 31, 2025 | -335.16 |
| Sep 30, 2025 | -443.78 |
| Jun 30, 2025 | -3.00 |
| Mar 31, 2025 | -10.18 |
| Dec 31, 2024 | -305.90 |
| Sep 30, 2024 | -244.44 |
| Jun 30, 2024 | -1,278.98 |
| Mar 31, 2024 | -347.23 |
| Dec 31, 2023 | -469.69 |
| Sep 30, 2023 | -84.73 |
| Jun 30, 2023 | -11.68 |
| Mar 31, 2023 | -49.01 |
| Dec 31, 2022 | -395.52 |
| Sep 30, 2022 | -747.23 |
| Jun 30, 2022 | -50.03 |
| Mar 31, 2022 | -78.76 |
| Dec 31, 2021 | 14.88 |
| Sep 30, 2021 | -9.54 |